Results of the intravenous administration of tropisetron in fibromyalgia patients.

Abstract

The observed effects on the symptoms of fibromyalgia of daily oral administration of 5 mg of the 5-HT3 receptor antagonist, tropisetron, for 10 days, could be maintained or exceeded with intravenous administration of only 2 mg of the formulation. Following a single i.v. injection of 2 mg tropisetron, a more rapid and profound reduction in pain was achieved than with 5 mg oral tropisetron per day. In individual cases, patients who had previously experienced no reduction in pain from 10 days of 5 mg oral tropisetron daily responded to i.v. therapy. A more favourable and persistent effect on pain, combined with a simultaneous significant improvement in various vegetative and functional symptoms was achieved with five days treatment with 2 mg tropisetron i.v. per day. The results outlined and the possibility for rapid improvements with drug treatment of fibromyalgia should be confirmed in randomised, placebo controlled trials.

• Authors: W Müller, T Stratz
• Journal: Scandinavian journal of rheumatology. Supplement (Scand J Rheumatol Suppl) Vol. 113 Pg. 59-62 ( 2000) ISSN: 0301-3847 [Print] Norway
• PMID: 11028834 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Indoles
• Serotonin Antagonists
• Tropisetron

Topics

• Administration, Oral
• Adult
• Aged
• Dose-Response Relationship, Drug
• Female
• Fibromyalgia (drug therapy, physiopathology)
• Humans
• Indoles (administration & dosage, adverse effects, therapeutic use)
• Injections, Intravenous
• Male
• Middle Aged
• Pain Measurement
• Serotonin Antagonists (administration & dosage, adverse effects, therapeutic use)
• Tropisetron